|
|
 |
Welcome to the online version of Neurosurgery Notes, the practice newsletter for Carolina Neurosurgery & Spine Associates. To find out more about the practice or to subscribe to our newsletter, click the links to the left. To read the articles in this issue, click below.
In This Issue:
Stent System Is Effective And Less Invasive In Preventing Stroke
Our Practice To Become Regional Training Site For Carotid Artery Stenting
 After receiving FDA approval last year, the use of stenting to clear blockages in the carotid arteries is on the rise. These stents are designed for use in patients who have experienced symptoms of a stroke or whose carotid artery has significant blockage, and who are not good candidates for carotid endarterectomy -- the traditional surgical option. Full story
VIDEO - click here to view an animation of the procedure
Carolina Neurosurgery & Spine Associates Is Among The First In The Country To Offer New Treatment for AVMs
Carolina Neurosurgery & Spine Associates will be one of the first in the country, and one of only three sites in North Carolina, to offer Onyx® Liquid Embolic System, a new FDA-approved treatment for arteriovenous malformations (AVMs). Onyx is a sealant that blocks these abnormal connections between veins and arteries in the brain using minimally invasive endovascular techniques. Full story
Endovascular Coiling Offers Minimally Invasive Option For Treating Unruptured Brain Aneurysms
 A minimally invasive treatment option available through Carolina Neurosurgery & Spine Associates is endovascular coiling. This procedure accesses the treatment area from within the blood vessel. The practice is the only neurosurgery group in the region, and one of only three in the Carolinas, performing the aneurysm coiling procedure. Full story
Our New Charlotte Office Opens Oct. 31st!
Patients with appointments on or after Oct. 31st should go to our new location at the corner of Baldwin and East Third Street. Our new 52,000-square-foot, two-story office will feature new and expanded services. See our next newsletter for more details.
|
 |
